Skip to content
Head to head

Taysha Gene Therapies vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TSHA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

TSHA -9.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
TSHAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price3.72515.02
Change today-1.33%-1.08%
1-year return-6.8%+22.0%
Market cap$1.21B$130.58B
52-week range3.46 – 7.30412.27 – 568.67
Valuation
P/E (TTM)-8.8633.14
P/E percentile, own 5-yr range22nd99th
P/B3.406.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.3415.32
Net profit (TTM)$-110.86M$3.88B
Revenue (TTM)$5.49M$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)-100.0%+11.8%
Gross margin--85.5%
Operating margin-2854.9%33.1%
Net margin-2728.0%30.7%
Free cash flow (TTM)$-135.57M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership99.5%96.8%
Insider activity (12mo)25 buy / 25 sell28 buy / 22 sell
Short interest (% of float)16.4%1.9%
Analyst consensus100% buy (4)95% buy / 5% hold (21)
Analyst price target$14 (+285%)$624 (+21%)
StockVane view
StockVane Quant RatingD (32)C (68)
Company
Employees996,400
Founded20191989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.